Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial

AIMS: To investigate efficacy and safety of the sodium–glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin administered as add‐on therapy to the dipeptidyl peptidase‐4 (DPP‐4) inhibitor teneligliptin in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: We conducted a multice...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadowaki, Takashi, Inagaki, Nobuya, Kondo, Kazuoki, Nishimura, Kenichi, Kaneko, Genki, Maruyama, Nobuko, Nakanishi, Nobuhiro, Iijima, Hiroaki, Watanabe, Yumi, Gouda, Maki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484989/
https://www.ncbi.nlm.nih.gov/pubmed/28177187
http://dx.doi.org/10.1111/dom.12898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484989/
https://www.ncbi.nlm.nih.gov/pubmed/28177187
http://dx.doi.org/10.1111/dom.12898

Ejemplares similares